Skip to main content
NeuroSense Therapeutics Ltd. logo

NeuroSense Therapeutics Ltd. — Investor Relations & Filings

Ticker · NRSN ISIN · IL0011809592 LEI · 254900UWMHXRH1IZPT20 US Manufacturing
Open in API
Filings indexed 281 across all filing types
Latest filing 2024-06-24 Regulatory Filings
Country IL Israel
Listing US NRSN

About NeuroSense Therapeutics Ltd.

https://www.neurosense-tx.com/

NeuroSense Therapeutics Ltd. is a late-clinical stage drug development company focused on discovering and developing treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS). The company's strategy is to create combined therapies that target multiple pertinent mechanisms involved in these complex conditions. Its lead drug candidate, PrimeC, is a unique fixed-dose combination of ciprofloxacin and celecoxib. Following a successful Phase 2b clinical trial (PARADIGM) that demonstrated a significant impact on slowing disease progression, NeuroSense is advancing PrimeC into a pivotal Phase 3 study. PrimeC has received Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The company is also exploring therapies for other neurodegenerative diseases.

Recent filings

Filing Released Lang Actions
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release dated June 24, 2024, titled 'NeuroSense Management Provides Corporate Update and First Quarter 2024 Financial Results.' The document states that the press release is furnished as Exhibit 99.1 and incorporates unaudited consolidated financial results. The document length is 2451 characters, which is relatively short and primarily serves to furnish a press release and financial results rather than presenting a full financial report. According to the rules, such documents that provide updates or press releases with financial results but are not comprehensive financial reports themselves are best classified as Regulatory Filings (RNS).
2024-06-24 English
REPORT OF FOREIGN PRIVATE ISSUER
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer filed with the SEC. It includes a press release about receiving a delisting notice from Nasdaq and the company's intention to appeal. The document is short (2117 characters) and primarily serves to furnish a press release rather than containing detailed financial data or a full report. It references the delisting notice but does not itself constitute a delisting announcement filing. Given the nature and length, this is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2024-06-21 English
PROSPECTUS SUPPLEMENT
Annual Report Classification · 95% confidence The document is a Form 6-K filed by NeuroSense Therapeutics Ltd. dated June 17, 2024. It includes a prospectus supplement and a report of a change in accounting method from IFRS to U.S. GAAP, with re-issued consolidated financial statements for the year ended December 31, 2023. The document contains detailed consolidated financial statements, an operating and financial review, and a consent of the independent registered accounting firm. The presence of audited financial statements and management's operating and financial review indicates this is a comprehensive financial report. Form 6-K is used by foreign private issuers to furnish reports to the SEC, often including annual or interim financial information. Since the document includes full financial statements and management discussion for a full fiscal year, it aligns with the characteristics of an Annual Report (10-K equivalent for foreign issuers). It is not merely an announcement or certification, but the actual report with substantive financial data and analysis. Therefore, the appropriate classification is Annual Report (10-K).
2024-06-17 English
PROSPECTUS SUPPLEMENT
Annual Report Classification · 95% confidence The document is a Form 6-K filed by NeuroSense Therapeutics Ltd. It includes a prospectus supplement and a re-issued set of consolidated financial statements for the year ended December 31, 2023, prepared under U.S. GAAP, replacing prior IFRS-based statements. The filing contains detailed financial statements, an operating and financial review, and the auditor's report. The presence of full financial statements and management's discussion indicates this is a comprehensive financial report for a full fiscal year. Although it is filed on Form 6-K (typically for foreign private issuers to report material information), the content is essentially an annual report equivalent, including audited financials and management's review. Therefore, the document should be classified as an Annual Report (10-K equivalent).
2024-06-17 English
REPORT OF FOREIGN PRIVATE ISSUER
Interim / Quarterly Report Classification · 95% confidence The document is a Form 6-K filed with the SEC by a foreign private issuer, NeuroSense Therapeutics Ltd., reporting a change in accounting method and re-issuing consolidated financial statements for the year ended December 31, 2023. It includes consolidated financial statements, an Operating and Financial Review and Prospects, and a consent of the independent registered accounting firm. The document is 3006 characters long, which is relatively short but contains substantive financial data and analysis, not merely an announcement or certification. Form 6-K is typically used for interim or periodic reports by foreign private issuers. The presence of financial statements and operating review indicates this is an Interim / Quarterly Report rather than a full Annual Report (10-K) or just an announcement. Therefore, the most appropriate classification is Interim / Quarterly Report (IR).
2024-06-17 English
REPORT OF FOREIGN PRIVATE ISSUER
AGM Information Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, NeuroSense Therapeutics Ltd., with the SEC. It includes exhibits for a Notice and Proxy Statement for the Annual General Meeting (AGM) and a Proxy Card. The document length is 1935 characters, which is relatively short and primarily serves to provide the proxy materials for the AGM. There is no detailed financial data or comprehensive report content present. According to the 'Menu vs Meal' rule, this is an announcement or provision of AGM-related materials rather than the full AGM report itself. Therefore, the appropriate classification is AGM Information (AGM-R).
2024-05-28 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.